Tag: Novo Nordisk
-
Novo Nordisk Halts Two More Phase 3 Ziltivekimab Trials After ZEUS Setback
Novo Nordisk has discontinued the Phase 3 HERMES and ATHENA trials of ziltivekimab after the earlier ZEUS failure raised doubts that IL-6 suppression would translate into cardiovascular benefit. ARTEMIS remains the key ongoing Phase 3 test of the program.
-
How Tirzepatide May Reduce Cardiovascular Risk
Tirzepatide combines GIP and GLP-1 receptor signaling to improve glucose, weight and other cardiometabolic factors associated with cardiovascular risk.
-
Pfizer Lands Metsera Acquisition After Novo Nordisk Bows Out of $10 B Bidding War
Pfizer’s acquisition of Metsera secures a high-potential obesity-drug pipeline — but because Metsera’s assets are early-stage, the deal carries meaningful regulatory and execution risk.
-
The Battle for Metsera: Pfizer and Novo Nordisk in a Fierce Takeover War
As the race for next-generation obesity treatments intensifies, two global pharma giants — Pfizer and Novo Nordisk — are locked in a fierce takeover battle over Metsera, a promising biotech with breakthrough GLP-1 assets. What began as a merger deal has escalated into a high-stakes legal and strategic war.